Management Forum Logo

Presented by
Management Forum

New EU (European Union) GMP (Good Manufacturing Practice) Annex 1 and its Impact on Pharmaceutical Manufacturers Training Course

Latest changes in the manufacturing requirements for sterile medicinal products

This free webinar will explain the reasons for the revision of Annex 1 and will address the changes and implications for pharmaceutical manufacturers. Topics to be covered will include how to prepare your Contamination Control Strategy (CCS) document, and how to adapt to the principles of Quality Risk Management. The expectations of the regulatory authorities and the questions that may be encountered in audits/inspections will also be discussed.

★★★★★ "Really enjoyed it - Thank you."

Recorded on 8 June 2023 »

Need help?  Watch now


The requirements of Annex 1, (which came into effect in August 2022), are applicable to the production of sterile pharmaceutical products. Manufacturers were given one year to adapt to the new guidelines, except for a part related to Lyophilization, where an additional year has been allowed to meet the Lyophilization criteria.

Since Annex 1 was first published, there have been numerous changes in technology, authority and patient expectations in GMP regulations.

A key element of Annex 1 is Contamination Control Strategy (CCS). Although this was presented as a new requirement, in fact contamination and cross-contamination were already mandatory requirements in facilities producing sterile medicinal products. The objective here is to include the measures taken by the manufacturing facility in a master document, which can be used periodically by senior management to ensure their facility meets the safety requirements.

Annex 1 refers to the importance of fulfilling the requirements set forth in ICH Q9 regarding Quality Risk Management. Interestingly, ICH completed the revision of Q9 in January 2023 and finally released it after 18 years of discussions.

Both sterile medical product manufacturers and the regulatory authorities emphasize the importance of evaluating the new Annex 1 according to the ICH Q9 guideline. 

This webinar will explain the reasons for the revision of Annex 1 and will address the changes and implications for pharmaceutical manufacturers. Topics to be discussed will include how to prepare your CCS document, and how to adapt to the principles of Quality Risk Management. The expectations of the regulatory authorities and the questions that may be encountered in audits/inspections will also be discussed.

This course is part of our GxP training (Good x Practice) course collection, which features a variety of topic areas to ensure you comply with the most recent quality guidelines. For more information on the latest EU GMP regulations, see our GMP training course covering the Annex 1.

Benefits of Attending

By participating in this webinar, you will receive detailed information about the new Annex 1, be brought up-to-date regarding the requirements, and the webinar documents will be a useful reference source for the future. 

This is a 90-minute free event, book your place now!

Who should attend?

  • Sterile Medicinal Product Manufacturers in the following departments:
  • Quality Assurance
  • Quality Control
  • Manufacturing
  • Aseptic Filling
  • Regulatory Affairs
  • IT

This webinar will also be of interest to:

  • Regulatory Authority Inspectors / Auditors
  • Pharmacy, chemistry, engineering students and new graduates

Mustafa Edik

Mustafa Edik is an Independent GMP Consultant and Auditor.  

After graduating as a Chemist from university, Mustafa began his 25 year plus career as a Laboratory Supervisor at Bayer, a German Pharmaceutical Company. After 15 years of working as a Quality Assurance Assistant Manager, Laboratory Supervisor, Pharmaceutical Quality Management Systems, and GMP Lead Auditor, he decided to continue his career as a Consultant. He has served the Turkish Atomic Energy Authority (TAEA) as Principal GMP Auditor and Consultant for 6 years. TAEA was audited by the Republic of Turkey Ministry of Health and granted GMP Certificate for 5 Radiopharmaceuticals. This success has won great acclaim from all health authorities and industry. 

He has prepared and presented various training courses and workshops to more than 8000 individuals from 150 International and local Pharmaceutical, Medical Device, and Cosmetics companies on GMP, GDP and Pharmaceutical Quality Management Systems. He has taken part in several International Pharmaceutical Facility Establishment projects as GMP Consultant and has also set up various Quality Management Systems for Local Pharmaceutical and Medical Device Companies.

While he was the Vice President of Quality and Technical Operations at a Quality Academia Training and Consultancy firm, he acquired and converted it into a 100 % Turkish Company. As the only IRCA Certificated Pharmaceutical Quality Management Systems and GMP Lead Auditor in Turkey, he currently conducts API, Excipient, Packaging Materials Suppliers and Manufacturers, Third Party Logistics Service Providers, Sterile and Non-Sterile Manufacturing Facilities Audits according to FDA, EMA, PIC /S, TMMDA, MHRA, TGA Health Canada, and WHO regulations and guidelines.

He finished his second university degree in Biopharmaceutical Sciences BSc (Hons) at Atlantic Technological University - Ireland. He is the author of chapter 6 of the book published by PDA named “Good Distribution Practices” and he is preparing his latest book on ‘GMP Audits’ which will be published by Taylor & Francis in 2023.


More details

Recorded on 8 June 2023


13:30-15:00 UK (London) (UTC+01)
14:30-16:00 Paris (UTC+02)
08:30-10:00 New York (UTC-04)
Course code 12982

View basket 

Reviews of IPI's New EU GMP Annex 1 and its Impact on Pharmaceutical Manufacturers training course

Really enjoyed it - Thank you.

Jun 8 2023

Michael Rieder
Quality Assurance - Validation, Janssen

Jun 8 2023

The presentation was very informative

Lethukuthula Manyaka
Locum Pharmacist , LocumSA

Jun 8 2023

Great content and relevant. Presentation was good and well explained.

Anita Vanderlaan
Qualified Person, Norbrook Laboratories Ltd

United Kingdom

  • Almac Group
  • Almac Group Limited
  • Anderson Law LLP
  • Ceresma Consultancy Ltd
  • Essential Pharma Ltd
  • Fresh Pak
  • Galderma (UK) Ltd
  • Guys Hospital
  • Kalvista Pharmaceuticals
  • knoell Animal Health
  • Moredun Scientific
  • NDA
  • NHS
  • Norbrook
  • Norbrook Laboratories
  • Norbrook Laboratories Limited
  • Norbrook Laboratories Ltd
  • Norbrook Labs
  • Norgine
  • Projective
  • RamsayPharma
  • Rosemont Pharmaceuticals Ltd
  • Roslinct
  • Sartorius
  • SGS Vitrology
  • SincasPharma
  • Terumo
  • Theramex
  • Torbay Pharmaceuticals
  • Vectura Group Limited
  • Wasdell group


  • Avertim
  • Inhouse
  • J&J
  • Janssen
  • Janssen biologics
  • Janssen BV
  • Janssen Pharmaceuticals
  • Uniqure


  • BakerHicks
  • Bumper Sciences
  • IBSA Institut Biochimique SA
  • Merck Healthcare
  • schott pharma
  • Sintetica SA
  • University Children's Hospital
  • Wollenweber GMP/GDP-Services


  • Alfasigma
  • Angelini Pharma S.p.A.
  • SciClone
  • Sifi
  • SIFI spa
  • ThermoFisher Scientific

United States of America

  • ALmatica Pharma LLC
  • Bausch + Lomb
  • BioMarin Pharmaceutical Inc
  • Emergent Biosolutions
  • Gerresheimer
  • Neurocrine Biosciences
  • Quality, Microbiology & Sterilization Services LLC


  • AvenCell
  • Boehringer Ingelheim
  • CHEPLAPHARM Arzneimittel GmbH
  • Esteve Pharmaceuticals GmbH
  • Garten
  • Syntegon Technology GmbH


  • Abdi İbrahim İlaç Sanayi ve Tic A.Ş.
  • Astellas pharma türkiye
  • Gen ilaç
  • Gensenta Pharma
  • MF


  • Avertim
  • Avertim SRL
  • Q-People
  • Qpeople
  • SGS


  • Ascendis Pharma A/S
  • Bavarian Nordic
  • Novo Nordisk
  • SSI
  • Statens Serum Institut


  • Adhara
  • Bumper sciences
  • Freelancer
  • SGS


  • Martin crehan
  • NSAI
  • Shorla Oncology
  • Teva
  • TUS

Slovak Republic

  • Imuna Pharm
  • IMUNA PHARM a.s.
  • IMUNA Pharm s.s.
  • imuna, a.s.
  • Saneca Pharmaceuticals a.s.


  • Gypto
  • Independent Pharmaceutical Consultant
  • mevac for vaccines


  • Boehringer Ingelheim
  • Bros
  • Demo


  • Antibiotice
  • Antibiotice S. A.
  • Antibiotice SA


  • CZ Vaccines
  • Faes Farma, S.A.


  • Pharmapark OÜ
  • Pharmapark Prodution


  • Egis
  • EGIS Pharmaceutical PLC


  • Cipla Ltd.
  • Self


  • Malta Medicines Authority
  • MMA

Saudi Arabia

  • Najran University
  • Pharmacy student


  • Profarma


  • ZETA GmbH


  • Besta Med Ltd.


  • NDA


  • Alvotech

Isle of Man

  • SEQ Limited


  • Ukko


  • Gentipharm


  • Profarma


  • famatiz


  • HSA

South Africa

  • LocumSA


  • Camurus AB


  • Mycenax Biotech

United Arab Emirates

  • Julphar

Multiple colleagues? See above for details of our discounts for 2, 3, or 4 delegates. For more, talk to one of our training experts to discuss how to:

Run this course conveniently and cost-effectively in-house for your staff and colleagues

Aleksandra Beer

Aleksandra BEER
Training expert

Yesim Nurko

Training expert

+44 (0)20 7749 4749